Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
Policy uncertainty lingered, and trade headlines remained unpredictable as President Trump continued to keep markets guessing. And yet, corporate earnings held up and equities proved surprisingly resilient. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential That staying power is exactly what stood out to Raymond James Chief Investment Officer Larry Adam, who sees 2025 as a reminder of how adaptable markets can be. “Despite heightened policy uncertainty and persistent geopolitical tensions, both proved remarkably resilient. Strong corporate earnings and AI enthusiasm propelled the S&P 500 to its third consecutive year of double-digit gains, while slowing – but still positive – economic growth and timely Federal Reserve rate cuts pushed Treasury yields lower,” Adam noted. With the calendar about to flip, Raymond James analysts are turning the
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.MarketBeat
- Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight [Yahoo! Finance]Yahoo! Finance
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 12/8/25 - Form SCHEDULE
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- LXEO's page on the SEC website